Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC

Article Immunology

Association Between AZD7442 (Tixagevimab-Cilgavimab) Administration and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Hospitalization, and Mortality

Jennifer Kertes et al.

Summary: During the fifth wave of Omikron-dominated COVID-19, intramuscular AZD7442 treatment among immunocompromised individuals was associated with a lower risk of SARS-CoV-2 infection and severe disease.

CLINICAL INFECTIOUS DISEASES (2023)

Add to Collection

Letter Oncology

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

Robert Stuver et al.

CANCER CELL (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies

Timothee Bruel et al.

Summary: There are differences in neutralizing activity of therapeutic antibodies against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages, and immunocompromised individuals treated with antibodies show elevated antibody levels but reduced neutralization against Omicron. Breakthrough infections with the Omicron variant are observed in some immunocompromised individuals despite antibody treatment.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19

Myron J. Levin et al.

Summary: A single dose of AZD7442 showed efficacy in preventing Covid-19 without evident safety concerns. The study suggests that AZD7442 may provide potential protection for individuals who have an inadequate response to vaccination or an increased risk of exposure.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Surgery

Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients

Ilies Benotmane et al.

Summary: Preexposure prophylaxis with cilgavimab-tixagevimab does not adequately protect kidney transplant recipients against the omicron variant.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Surgery

Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave

Ayman Al Jurdi et al.

Summary: The use of tixagevimab/cilgavimab in vaccinated solid organ transplant recipients during the Omicron wave is safe and associated with a lower risk of breakthrough SARS-CoV-2 infection. Adverse events are uncommon, and most are mild.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Article Infectious Diseases

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients

Yann Nguyen et al.

Summary: This study aimed to investigate the incidence and outcomes of COVID-19 among immunocompromised patients receiving tixagevimab/cilgavimab as preexposure prophylaxis. The results showed a low rate of infections and severe illnesses among patients treated with tixagevimab/cilgavimab, suggesting the effectiveness of this preventive strategy for severely immunocompromised patients.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

Add to Collection

Article Critical Care Medicine

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Hugh Montgomery et al.

Summary: This study evaluated the safety and efficacy of tixagevimab-cilgavimab in preventing severe COVID-19 or death in non-hospitalized adults. The results showed that a single dose of tixagevimab-cilgavimab significantly reduced the risk of progression to severe COVID-19 or death, with favorable safety.

LANCET RESPIRATORY MEDICINE (2022)

Add to Collection

Letter Hematology

Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Societe Francophone de Greffe de Moelle et de Therapie cellulaire (SFGM-TC) multicentre cohort study

Alienor Xhaard et al.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: a multicentric retrospective study of SFGM-TC

Related references

Export Citation

Share Paper